• 

  Partial breast radiotherapy after breast conservation surgery for early breast cancer: 5-year outcomes from the IMPORT LOW (CRUK/06/003) phase III randomised controlled trial 

  Coles, C; Griffin, C; Kirby, A; Titley, J; Agrawal, R; Alhasso, A; Bhattacharya, I; Brunt, M; Ciurlionis, L; Chan, C; Donovan, E; Emson, M; Harnett, A; Haviland, J; Hopwood, P; Jefford, M; Kaggwa, R; Sawyer, E; Syndikus, I; Tsang, Y; Wheatley, D; Wilcox, M; Yarnold, J; Bliss, J
• 

  Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer. 

  Yang, JC; Ou, SI; De Petris, L; Gadgeel, S; Gandhi, L; Kim, DW; Barlesi, F; Govindan, R; Dingemans, AC; Crino, L; Lena, H; Popat, S; Ahn, JS; Dansin, E; Golding, S; Bordogna, W; Balas, B; Morcos, PN; Zeaiter, A; Shaw, AT (2017-07-05)

  INTRODUCTION: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report pooled efficacy and safety data after 15 and 18 months' longer follow-up ...
• 

  LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. 

  Scagliotti, GV; Gaafar, R; Nowak, AK; Reck, M; Tsao, AS; van Meerbeeck, J; Vogelzang, NJ; Nakano, T; von Wangenheim, U; Velema, D; Morsli, N; Popat, S (2017-03-22)

  Malignant pleural mesothelioma (MPM) is a rare but aggressive disease: median survival is 6 to 9 months if untreated. Standard first-line treatment for patients with unresectable MPM is cisplatin/pemetrexed, with a median ...
• 

  Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols 

  Ferrari, A; Trama, A; De Paoli, A; Bergeron, C; Merks, JHM; Jenney, M; Orbach, D; Chisholm, JC; Gallego, S; Glosli, H; De Salvo, GL; Botta, L; Gatta, G; Bisogno, G; Grp, RW (2017-06)
• 

  11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 

  Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; de Azambuja, E; Castro, G; Untch, M; Smith, I; Gianni, L; Baselga, J; Al-Sakaff, N; Lauer, S; McFadden, E; Leyland-Jones, B; Bell, R; Dowsett, M; Jackisch, C; Herceptin Adjuvant (HERA) Trial Study Team (2017-03-25)

  BACKGROUND: Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast ...
• 

  Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. 

  Meyer, T; Fox, R; Ma, YT; Ross, PJ; James, MW; Sturgess, R; Stubbs, C; Stocken, DD; Wall, L; Watkinson, A; Hacking, N; Evans, TRJ; Collins, P; Hubner, RA; Cunningham, D; Primrose, JN; Johnson, PJ; Palmer, DH (2017-08)

  BACKGROUND: Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced ...
• 

  Adherence to guidelines for adult (non-GIST) soft tissue sarcoma in the Netherlands: a plea for dedicated sarcoma centers 

  van der Graaf, W
• 

  The results of local excision with or without postoperative adjuvant chemoradiotherapy for early rectal cancer among patients choosing to avoid radical surgery. 

  Balyasnikova, S; Read, J; Tait, D; Wotherspoon, A; Swift, I; Cunningham, D; Tekkis, P; Brown, G (2016-07-30)

  The study aimed to establish the oncological outcome of patients who opted for close surveillance with or without adjuvant chemoradiotherapy (CRT) rather than radical surgery after local excision (LE) of early rectal cancer ...
• AN UPDATE ON THE MANAGEMENT OF SPORADIC DESMOID-TYPE FIBROMATOSIS: A EUROPEAN CONSENSUS INITIATIVE BETWEEN SARCOMA PATIENTS EURONET (SPAEN) AND EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) / SOFT TISSUE AND BONE SARCOMA GROUP (STBSG) 

  van der Graaf, W
• 

  Hypofractionation trials and radiobiology of prostate cancer. 

  Gulliford, S; Hall, E; Dearnaley, D (2017-03)
• 

  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. 

  Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bossi, A; Bristow, R; Carver, B; Castellano, D; Chung, BH; Clarke, N; Daugaard, G; Davis, ID; de Bono, J; Dos Reis, RB; Drake, CG; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, F; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Higano, CS; James, N; Kantoff, P; Kellokumpu-Lehtinen, PL; Khauli, RB; Kramer, G; Logothetis, C; Maluf, F; Morgans, AK; Morris, MJ; Mottet, N; Murthy, V; Oh, W; Ost, P; Padhani, AR; Parker, C; Pritchard, CC; Roach, M; Rubin, MA; Ryan, C; Saad, F; Sartor, O; Scher, H; Sella, A; Shore, N; Smith, M; Soule, H; Sternberg, CN; Suzuki, H; Sweeney, C; Sydes, MR; Tannock, I; Tombal, B; Valdagni, R; Wiegel, T; Omlin, A (2017-06-24)

  BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of ...
• 

  Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. 

  McNamara, MG; Bridgewater, J; Lopes, A; Wasan, H; Malka, D; Jensen, LH; Okusaka, T; Knox, JJ; Wagner, D; Cunningham, D; Shannon, J; Goldstein, D; Moehler, M; Bekaii-Saab, T; Valle, JW (2017-04-12)

  BACKGROUND: Outcomes in younger (<40 years) and elderly (≥70 years) patients with advanced biliary cancer (ABC) receiving palliative chemotherapy are unclear. This study assessed outcomes in those receiving monotherapy or ...
• 

  Accelerated versus standard epirubicin followed by CMF versus capecitabine as adjuvant therapy of breast cancer: results of the randomised UK TACT2 trial (CRUK/05/19) 

  Bliss, J; banerji, J; Gillman, A; Morden, J
• 

  Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply. 

  Smyth, EC; Allum, WH; Rowley, S; Langley, RE; Cunningham, D (2017-05)
• 

  Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. 

  Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; Yuan, L; Begum, R; Eltahir, Z; Wotherspoon, A; Fernandez, AM; Mendes, LST; de Castro, DG; Wilson, SH; Proszek, P; To, YM; Hawkes, E; Roy, A; Cunningham, D; Rao, S; Watkins, D; Starling, N; Bowcock, AM; Chau, I (2017-04-11)

  This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ...
• 

  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

  James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-06-03)

  Background Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a ...
• 

  Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. 

  Wagner, AJ; Banerji, U; Mahipal, A; Somaiah, N; Hirsch, H; Fancourt, C; Johnson-Levonas, AO; Lam, R; Meister, AK; Russo, G; Knox, CD; Rose, S; Hong, DS (American Society of Clinical Oncology, 2017-04-20)

  Purpose To evaluate MK-8242 in patients with wild-type TP53 advanced solid tumors. Patients and Methods MK-8242 was administered orally twice a day on days 1 to 7 in 21-day cycles. The recommended phase II dose (RP2D) was ...
• 

  UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST). 

  Judson, I; Bulusu, R; Seddon, B; Dangoor, A; Wong, N; Mudan, S (2017)

  BACKGROUND: Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues. Gastrointestinal stromal tumour (GIST) is the commonest STS and arises within the wall of the gastrointestinal (GI) tract. While most ...
• 

  Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. 

  Spain, L; Walls, G; Julve, M; O'Meara, K; Schmid, T; Kalaitzaki, E; Turajlic, S; Gore, M; Rees, J; Larkin, J (2016-10-25)
• 

  Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. 

  Dreyling, M; Morschhauser, F; Bouabdallah, K; Bron, D; Cunningham, D; Assouline, SE; Verhoef, G; Linton, K; Thieblemont, C; Vitolo, U; Hiemeyer, F; Giurescu, M; Garcia-Vargas, J; Gorbatchevsky, I; Liu, L; Koechert, K; Peña, C; Neves, M; Childs, BH; Zinzani, PL (2017-06-14)

  Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against the α- and δ- isoforms. Patients and methods: This phase II study evaluated the response rate of ...

View more